Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic

Novo Nordisk's weaker results indicate mounting pressure in the weight-loss drug market that it once dominated. The maker of Ozempic and Wegovy is facing tougher competition, slower demand, and pricing pressures—and has now cut its full-year outlook for the fourth time in 2025. Novo Nordisk lowered its guidance in part due to disappointing demand for Ozempic. Eric Thayer / Bloomberg via Getty Images Close Key Takeaways U.S.-listed shares of Novo Nordisk (NVO) fell after the drugmaker scaled back its outlook ...